抗肥胖药物的营养注意事项。

IF 4.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Obesity Pub Date : 2024-06-10 DOI:10.1002/oby.24067
Jaime P. Almandoz, Thomas A. Wadden, Colleen Tewksbury, Caroline M. Apovian, Angela Fitch, Jamy D. Ard, Zhaoping Li, Jesse Richards, W. Scott Butsch, Irina Jouravskaya, Kadie S. Vanderman, Lisa M. Neff
{"title":"抗肥胖药物的营养注意事项。","authors":"Jaime P. Almandoz,&nbsp;Thomas A. Wadden,&nbsp;Colleen Tewksbury,&nbsp;Caroline M. Apovian,&nbsp;Angela Fitch,&nbsp;Jamy D. Ard,&nbsp;Zhaoping Li,&nbsp;Jesse Richards,&nbsp;W. Scott Butsch,&nbsp;Irina Jouravskaya,&nbsp;Kadie S. Vanderman,&nbsp;Lisa M. Neff","doi":"10.1002/oby.24067","DOIUrl":null,"url":null,"abstract":"<p>The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"32 9","pages":"1613-1631"},"PeriodicalIF":4.2000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24067","citationCount":"0","resultStr":"{\"title\":\"Nutritional considerations with antiobesity medications\",\"authors\":\"Jaime P. Almandoz,&nbsp;Thomas A. Wadden,&nbsp;Colleen Tewksbury,&nbsp;Caroline M. Apovian,&nbsp;Angela Fitch,&nbsp;Jamy D. Ard,&nbsp;Zhaoping Li,&nbsp;Jesse Richards,&nbsp;W. Scott Butsch,&nbsp;Irina Jouravskaya,&nbsp;Kadie S. Vanderman,&nbsp;Lisa M. Neff\",\"doi\":\"10.1002/oby.24067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.</p>\",\"PeriodicalId\":215,\"journal\":{\"name\":\"Obesity\",\"volume\":\"32 9\",\"pages\":\"1613-1631\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24067\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/oby.24067\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24067","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

新近批准的抗肥胖药物(AOMs)平均可使体重减轻≥15%,其疗效的提高和普遍良好的安全性代表了肥胖症治疗领域的重大进展。本综述旨在为接受 AOMs 治疗的患者的营养评估、管理和监测提供实用的循证建议。在治疗前,临床医生可以确定患者原有的营养风险因素,并就蛋白质、膳食纤维、微量元素和液体的推荐摄入量向患者提供咨询。在 AOMs 治疗期间,持续监测有助于及早发现和处理胃肠道症状或营养或液体摄入不足的情况。此外,还应关注可能影响治疗效果和生活质量的其他因素,如体力活动、社交和情绪健康等。在使用 AOMs 治疗的过程中,临床医生可以发挥积极作用,为肥胖症患者提供支持,以改善他们的健康和福祉,促进最佳营养和医疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nutritional considerations with antiobesity medications

Nutritional considerations with antiobesity medications

The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Obesity
Obesity 医学-内分泌学与代谢
CiteScore
11.70
自引率
1.40%
发文量
261
审稿时长
2-4 weeks
期刊介绍: Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信